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Abstract
Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous condition characterized by occasional
exacerbations. Identifying clinical subtypes among patients experiencing COPD exacerbations (ECOPD) could help better
understand the pathophysiologic mechanisms involved in exacerbations, establish different strategies of treatment, and
improve the process of care and patient prognosis. The objective of this study was to identify subtypes of ECOPD patients
attending emergency departments using clinical variables and to validate the results using several outcomes. We evaluated
data collected as part of the IRYSS-COPD prospective cohort study conducted in 16 hospitals in Spain. Variables collected
from ECOPD patients attending one of the emergency departments included arterial blood gases, presence of
comorbidities, previous COPD treatment, baseline severity of COPD, and previous hospitalizations for ECOPD. Patient
subtypes were identified by combining results from multiple correspondence analysis and cluster analysis. Results were
validated using key outcomes of ECOPD evolution. Four ECOPD subtypes were identified based on the severity of the
current exacerbation and general health status (largely a function of comorbidities): subtype A (n = 934), neither high
comorbidity nor severe exacerbation; subtype B (n = 682), moderate comorbidities; subtype C (n = 562), severe
comorbidities related to mortality; and subtype D (n = 309), very severe process of exacerbation, significantly related to
mortality and admission to an intensive care unit. Subtype D experienced the highest rate of mortality, admission to an
intensive care unit and need for noninvasive mechanical ventilation, followed by subtype C. Subtypes A and B were
primarily related to other serious complications. Hospitalization rate was more than 50% for all the subtypes, although
significantly higher for subtypes C and D than for subtypes A and B. These results could help identify characteristics to
categorize ECOPD patients for more appropriate care, and help test interventions and treatments in subgroups with poor
evolution and outcomes.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a complex
and heterogeneous condition with various clinical manifestations.
A number of variables besides forced expiratory volume in one
second (FEV1) have been used to establish the severity of COPD,
gauge its prognosis, and guide treatment strategies [1]. In the
1950s, a binomial categorization identified COPD patients as pink
puffers or blue bloaters [2], a system that has long been
abandoned. Yet there is continuing interest in using clinical and
pulmonary function variables, biomarkers, and x-ray images to
identify different phenotypes of COPD patients, that may help
predict outcomes [1,3]. Most of this work currently focuses on
identifying markers related to phenotypic characteristics among
stable COPD patients [4–7].
Exacerbations of COPD (ECOPD) are common among patients
with this condition and they occur among patients with a wide
range of airway obstruction [8]. These sudden worsenings of
COPD contribute to disease progression, reduce quality of life,
increase the risk of death, and account for substantial use of
healthcare resources [9–11]. Pozo-Rodrı´guez et al. described
variability across hospitals in resource, organization, patient’s
characteristics, process of care and outcomes for COPD patients in
Spain [12]. Some investigators have identified COPD exacerba-
tion phenotypes with respect to inflammation and etiology [13,14].
However, to the best of our knowledge, no published studies have
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aimed to identify subtypes of ECOPD patients attending
emergency departments (EDs) based on general clinical practice.
Grouping ECOPD patients into subtypes could help improve our
understanding of the pathophysiologic mechanisms involved in
exacerbations, establish more effective treatment strategies, and
improve the process of care and patient prognosis in clinical
practice.
The objective of the study was to identify subtypes of ECOPD
patients. To do this, we combined multiple correspondence
analysis and cluster analysis to analyze clinical data obtained in
an observational prospective cohort study of ECOPD patients
attending various EDs. We then validated the subtypes by
estimating their relationships with key outcomes such as short-
term evolution of ECOPD, mortality, the need for hospitalization,
and other key outcomes.
Methods
Subjects and data collection
A detailed description of the Investigacion en Resultados y
Servicios de Salud COPD (IRYSS-COPD) Appropriateness Study
has been reported previously [15]. This prospective cohort study
included subjects from 16 hospitals in Spain. Patients with an
ECOPD attending the EDs of any of the hospitals between June
2008 and September 2010 were informed of the goals of the study
and invited to voluntarily participate in it. All who agreed to
participate provided written consent. All information was kept
confidential.
Data from several time points were collected in the study:
during the patient’s evaluation in the ED; at the time the decision
was made to hospitalize the patient or discharge him or her to
home; in the medical ward (if hospitalized); and up to one week
after the index ED visit (among those discharged from the ED to
home). Most of the recorded variables were categorical or were
categorized based on clinical criteria. The variables selected to
identify ECOPD subtypes were collected during the patient’s
evaluation in the ED, as previously described [15].
Numerous outcome variables were collected in the study. For
the purpose of this study, we concentrated on outcomes related to
the short-term evolution of ECOPD—those occurring in the
hospital for patients admitted from the ED or during the first week
after the index ED visit for those discharged to home. The selected
outcome variables were:
- Death.
- Admission to an intensive care unit (ICU) in the hospital,
which includes patients requiring invasive mechanical venti-
lation (IMV) or those experiencing cardiac arrest.
- Need for noninvasive mechanical ventilation (non-IMV) for
more than two days when it was not needed before admission
or admission to an intermediate respiratory care unit (IRCU)
for more than two days.
- Other serious complications, which includes shock, cardiac
arrhythmia, myocardial ischemia, pulmonary embolism,
pneumonia, pneumothorax, or decompensated diabetes, as
previously defined [15].
- Need for hospitalization.
Statistical analysis
Multivariate techniques such as factor analysis (FA), multiple
correspondence analysis (MCA), and cluster analysis (CA) have
been widely used to differentiate groups of individuals [5,6]. The
aim of techniques such as FA and MCA is to synthesize
information into a few components that retain the maximum
amount of information generally contained in a large number of
original variables, making data interpretation feasible or easier
[16]. The main difference between these methods is that FA is
designed for continuous variables while MCA deals with
qualitative variables [17].
MCA was the selected as the multivariate technique for the
analysis because the variables were categorical. In the MCA
framework, variables included in the analysis are called active
variables. Illustrative variables are defined as such variables that
are not active, it means that they are not included in the analysis,
but they are added to the results in order to check their association
with the active variables.
We performed MCA on all subjects included in the study. All
variables collected for the initial evaluation of ECOPD patients in
the EDs were included in the analysis as active variables. Active
variables were age (,70 or $70); baseline severity of COPD as
measured by FEV1%, (#50, 50–80 or $80); number of COPD-
related hospitalizations in the previous year (0–1, 2 or $3); need
for oxygen therapy (OT) at home (yes or no); baseline treatment
with continuous positive airway pressure (CPAP) or non-IMV (yes
or no); hemodynamic instability (HI) (yes or no); consciousness
level measured by the Glasgow Coma Scale (GCS) (,15 or 15)
[18]; arterial blood gas parameters, including pH (,7.26, 7.26–
7.35, $7.35), PCO2 (#45, 45–55, 55–65, .65) and PO2 (#45,
45–60, .60); the Charlson Comorbidity Index (CCI) (0–1 or .1)
[19]; and the presence of comborbidities such as diabetes (yes or
no) and cardiac disease (yes or no).
A category is defined as each of the level of a categorical
variable. MCA is not a confirmatory technique, but rather an
exploratory one. It provides descriptive patterns or components
based on the categories of the original active variables. (Greenacre
provides excellent detail on the use of MCA in medical research
[17]). We used MCA for transforming the information contained
in the original categorical variables into continuous factors. Each
factor can be interpreted as a component of the health status
derived from the original active variables. The categories of the
active variables were represented on the continuous factors
resulting from the MCA by a numeric value and a positive/
negative sign, both of which are used for interpretation.
Interpretation of the results provided by MCA is done based on
the graphical displays or maps given by any two factors. The
relative position of the category points in the maps indicates the
level of similarity or association between the categories. The closer
the points are, stronger is the relationship between the categories.
Many arterial blood gas measurements were missing [15]. To
derive information related to the missingness pattern and its
relationship with outcomes, missing values were retained in the
analysis as additional categories for each active variable. Outcome
variables were included in the analysis as illustrative variables in
order to describe the relationship of each variable category with
the outcomes.
CA organizes information from apparently heterogeneous
individuals into relatively homogeneous groups based on values
of different variables. Combining CA with MCA places subjects
into groups suggested by data—not defined a priori—such that
subjects in a given group are similar to each other and subjects in
different groups are dissimilar.
CA was performed using the relative position of the categories
given by the MCA components [20]. Therefore, the components
provided by the MCA were used to differentiate groups of
individuals. The number of groups was selected based on
minimum inertia lost [21].
All statistical analyses were performed using R v2.13.0 [22].
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Results
A total of 2,487 subjects were included in the study. Table 1
summarizes the variables collected upon arrival in the ED for all
patients and across the four subtypes of ECOPD (described later).
Statistically significant differences between subtypes were observed
in age, previous COPD-related hospitalizations, baseline FEV1%,
previous need for treatment (OT, CPAP or non-IMV), arterial
blood gasses (pH, PCO2, PO2), O2 saturation, CGS, CCI and
presence of diabetes and cardiac disease (p,0.001). Distribution of
the variables with missing observations is shown in Table 2.
Results from the MCA show that three components explain
70.2% of the variability in the data. The first component was
primarily associated with the presence or absence of arterial blood
gases. The second component was associated with the acuteness of
the exacerbation. The third component was related to the general
health status and presence of comorbidities.
Figure 1 shows the maps created by the second and third
components with respect to the first. The horizontal axis
represents the first component and the vertical axes represent
the second component (a) and the third component (b),
respectively. Categories located in the right part of the maps
included having a missing gas analysis and, therefore, no pH,
PCO2, or PO2 values. The nonmissing categories of these
variables were located in the left part with the rest of the active
variables. As regards as the vertical position, the missing categories
of the variables that measures blood gasses were located at the
central part of both maps. It means that having a missing blood
gas analysis was related neither to the acuteness of the
exacerbation nor to the comorbidity status. Moreover, relative
position of the outcomes in the maps also shows that the
missingness pattern was not significantly related to outcomes.
Variables well represented in the second component were
arterial blood gases (pH, PCO2, PO2), need for OT at home,
previous treatment with CPAP or non-IMV, GCS, baseline
FEV1%, and previous hospitalizations due to ECOPD. Categories
significant at the negative (bottom) part of the graph were pH,
7.26; 7.26#pH,7.35; PO2#45, PCO2.65, 55,PCO2 #65;
previous treatment with CPAP or non-IMV; need for OT at
home, GCS,15; baseline FEV1%#50%, and two or more
COPD-related hospitalizations in the previous year. Significant
categories at the positive (top) part of the graph were PCO2#45;
PO2.60; pH$7.35; no need for OT at home, and baseline
FEV1%.50%. Therefore, the second component could be
interpreted as a measure of the acuteness of the exacerbation,
where bottom part shows characteristics significantly related to a
more acute exacerbation whereas top part shows characteristics
related to a less acute exacerbation. All the outcomes were very
well represented by this component. The three outcomes related to
the poorest evolution of ECOPD (death, ICU admission, and need
for non-IMV for more than two days) were all located in the
bottom part of the graph, whereas other serious complications
were located in the top part and the need for hospitalization in the
central part.
Variables well represented in the third component were age,
CCI, diabetes, and cardiac disease. CCI#1, no diabetes, no
cardiac disease, and age,70 years old were significantly located in
the positive part (top) of the graph while CCI.1, presence of
diabetes, presence of cardiac disease, and age $70 years were
significantly located in the negative part (bottom). Thus, the third
component could be interpreted as a general health status, highly
related to comorbidities. Bottom part shows characteristics
significantly related to the presence of comorbidities and older
patients, and top part shows characteristics related to younger
subjects with less comorbidities. Outcomes were also well
represented in the third component. Admission to an ICU and
need for non-IMV for more than two days were located in the top
part of the graph; mortality was located in the bottom part,
whereas other serious complications and need for hospitalization
were located in the center.
Figure 2 shows the two-dimensional distribution created by
graphing the second and third components. The relative positions
of the five outcome variables are projected onto the graph. The left
side of the graph contains the most severe outcomes: admission to
an ICU and need for non-IMV for more than two days were
located in the top-left part of the graph; mortality was located in
the bottom-left part. Other serious complications were located in
the central-right part and the need for hospitalization was located
in the central-left part.
After applying CA to these results, four subtypes of ECOPD
patient were identified (Figure 3). Type A had the least severe
ECOPD, type D the most severe. Subjects are represented in
Figure 2 using different colors for these four subtypes.
Table 1 shows the distribution of the main variables collected in
the ED for all patients and by COPD subtype. The percentage of
patients with altered pH, PCO2, or PO2 was significantly higher in
subtype D than the others. The percentage of patients with an
altered GCS or greater deterioration of baseline pulmonary
function (FEV1%#50; need for OT, CPAP or non-IMV) was
significantly higher in subtype D than the others. Mean O2
saturation in subtype D (78.3%) was significantly lower than the
other subtypes. The percentage of patients with more than two
COPD-related hospitalizations in the previous year was approx-
imately 30% in subtype C, 16% in subtype D and less than 5% in
subtypes A and B. Mean age was significantly higher in subtypes B
and C than in subtypes A and D. The percentage of patients with
CCI.1 was significantly lower in subtype A (16.6%) than in the
others. The percentage of patients with diabetes or cardiac disease
was significantly higher in subtype C (49% and 48%, respectively)
than in the other classes. All of the previously mentioned
differences were statistically significant (p,0.001).
Associations between the subtypes and the outcomes are shown
in Table 3. Among the 934 (38%) patients in subtype A, 54.3%
were hospitalized, 27.9% had one or more negative outcomes and
only 2.7% experienced one of the three most severe outcomes.
Subtype B included 682 (27%) patients, 2.9% with one of the three
more severe outcomes and 26.7% with other serious major
complications. Subtype C included 562 (23%) patients, of whom
3.4% died and 5.2% were admitted to an ICU or needed non-
IMV for more than two days. Subtype D included 309 (12%)
patients, of whom 6.2% died and 26.6% were admitted to an ICU
or needed non-IMV for more than two days. The distribution of
patients across the subtypes was significantly associated with the
five outcomes (p,0.001).
Discussion
In a prospective cohort of 2,487 patients evaluated for ECOPD
in one of 16 EDs, an original statistical approach identified four
subtypes associated with different short-term outcomes. To the
best of our knowledge, this is the first study to have focused on the
development of a typology of ECOPD patients requiring ED
evaluation and their association with short-term evolution of
ECOPD.
Patients with an ECOPD attending an ED can be categorized
by two main components: one regarding the severity or acuteness
of the current exacerbation (shown graphically by the second
factor, where negative values were associated with a more severe
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Table 2. Distribution of observed and missing values.
Observed values
n (%)
Missing values
n (%)
Age* 72.8 (9.67) 1 (0.04)
Baseline FEV1% 418 (16.8)
$50 76 (3.7)
30,FEV1%,50 611 (29.5)
#30 1382(66.8)
Diabetes mellitus 532 (21.5) 18 (0.7)
Cardiac disease 536 (21.6) 16 (0.6)
Heart rate at arrival $120 237 (10.2) 158 (6.3)
pH 192 (7.7)
$7.35 1991 (57.2)
7.26–7.34 250 (10.9)
,7.26 54 (2.3)
PCO2 333 (13.4)
#45 1232 (57.2)
46–55 484 (22.5)
56–65 241 (11.2)
.65 197 (9.2)
PO2 209 (8.4)
.60 1134 (49.8)
46–60 847 (37.2)
#45 297 (13.0)
Abbreviations used in the text: forced expiratory volume in one second (FEV1%).
*Represented as mean (standard deviation).
doi:10.1371/journal.pone.0098580.t002
Figure 1. Graphical displays of the first component derived from the multiple correspondence analysis. Full legend: Maps created by
the second (a) and the third (b) components with respect to the first one, respectively. Black dots represent the categories of the active variables. The
closer the points are, stronger is the relationship between the categories. The horizontal axis in both graphs represents the first component,
interpreted as observed (left side) vs. missing (right side) arterial blood gases. (a) The second component, vertical axis, represents the severity of the
exacerbation or the acute COPD process, more acute (bottom side) vs. less acute (top side). (b) The third component, vertical axis, represents the
comorbidity status, more severe (bottom side) vs. less severe (top side). Blue dots represent the relative position of the outcomes.
doi:10.1371/journal.pone.0098580.g001
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disease process and positive values were associated with a less
severe process), and the other related to general health status such
as age or comorbidities (shown graphically by the third factor,
where positive values were associated with fewer comorbidities and
negative values were associated with more comorbidities). These
findings emphasize the importance of comorbidities such as
diabetes and heart disease among ECOPD patients, as other
investigators have shown [23], not just among stable COPD
patients, as has been recently published [24–26].
In our hierarchy, patients were first classified based on
comorbidity status, followed by the severity of the exacerbation
or the acute COPD process. At that point, comorbidity status
again helped discriminate between two subtypes.
The four subtypes (A, B, C, and C) provide a typology of
ECOPD patients attending an ED. Subtype A included patients
generally less than 70 years old with an FEV1% close to 50% and a
low rate of comorbidities (1.8%) based on the CCI and the absence
of heart disease or diabetes; arterial blood gases were in the
medium range with respect to the entire cohort. Subtype B
included patients with a mean age of 76 years and moderate
airway obstruction; approximately 30% had comorbidities; arterial
blood gases showed milder deterioration. Subtype C included
patients with a mean age of 75 years, similar to subtype B, but with
severe obstruction (mean FEV1% of 41%, which represent
statistically greater obstruction than in subtypes A and B) and
higher comorbidity status (49%). These were strongly related to
mortality and other serious complications. Arterial blood gases in
subtype C were also more altered than in subtypes A and B.
Subtype D, which represented the group with the greatest severity
of ECOPD, included patients with the most severe airflow
limitation at baseline and the most altered arterial gas values.
Figure 2. Map created by the second and third components derived from the multiple correspondence analysis. Full legend: The
horizontal axis, second component, can be interpreted as an index of the severity of the exacerbation or the acute COPD process, more acute (left
side) vs. less acute (right side). The vertical axis, third component, can be interpreted as an index of the comorbidity status, more severe (bottom) vs.
less severe (top). Black dots in the plane represent the categories of the active variables included in the multiple correspondence analysis, only the
most representative ones were labeled. The closer the points are, stronger is the relationship between the categories. Relative positions of the
subjects in this plane are represented by different colors, depending on the subtype provided by the cluster analysis. Large blue dots represent the
relative position of the outcomes.
doi:10.1371/journal.pone.0098580.g002
Figure 3. Partial dendrogram obtained from the cluster
analysis. Full legend: The dendogram represents the results from
the cluster analysis performed with the three components obtained
from the multiple correspondence analysis. The graphical display
includes an easy interpretation of the partition and a brief description
of the resulting groups.
doi:10.1371/journal.pone.0098580.g003
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Comorbidities in this group were in an intermediate range with
respect to the entire cohort. Patients in this group were more likely
to have severe evolution of ECOPD and had the highest mortality
rate. Overall, 65% of patients who died were concentrated in
subtypes C and D; 86% of those admitted to an ICU were in
subtypes C and D; and 82% of those who needed non-IMV for
more than two days were in subtype D. Patients with other serious
complications were distributed mainly in subtypes A (43%) and B
(33%). One remarkable result of our study is that ECOPD
severity, including hospitalization, ICU admission, and need for
non-IMV, was highly related to the severity of the current
exacerbation, while mortality was related to both the severity of
the current exacerbation (in this case directly associated with the
severity of airway obstruction) and poor general health status as
reflected by the presence of comorbidities.
Current information about COPD phenotypes has been derived
mainly from patients with stable COPD [5–7]. To date, three
main phenotypes have been identified and prospectively validated
against hospitalization and mortality during a 4 year follow-up.
One, labeled by Garcia-Aymerich et al. as the ‘‘severe respiratory
COPD’’ [7], has a high level of dyspnea, severe obstruction, and
low level of severe comorbidities (mainly diabetes and heart
disease). The second phenotype, labeled ‘‘systemic COPD’’ [7],
has significant comorbidities plus moderate to severe airway
obstruction. The third phenotype, called ‘‘ moderate respiratory
COPD’’ has a lower level of dyspnea, a lower rate of
comorbidities, and mild to moderate airway obstruction [7].
Our data show that these classifications represent a continuum
when patients with ECOPD are included. The severe respiratory
phenotype is comparable to subtype D in our study and the
systemic COPD phenotype is similar in general characteristics to
our subtype C. Our subtype D includes patients with the most
severe exacerbations, a high rate of exacerbation-related hospital-
ization, the poorest evolution of COPD during admission, and the
highest rate of mortality. In our study, the number of COPD-
related hospitalizations in the previous year was significantly
higher in subtypes C and D than in subtypes A and B, related to
both comorbidities and level of airway obstruction. The number of
previous COPD-related hospitalizations was not evaluated in
other studies: Garcia-Aymerich et al. [7] dealt with patients at
their first hospitalization and Burgel et al. [5,6] did not report
information about prior hospitalizations.
In our study, baseline mean FEV1% was lower than 50% in both
subtypes A and C, although it was higher in A (47.2%) than C
(40.9%), representing significantly more severe airway obstruction
in subtype C. Moreover, the comorbidity level was quite different
between these groups, with a higher CCI and higher prevalence of
heart disease and diabetes in subtype C. This difference is reflected
in the different outcomes, such as mortality rate, ICU admission,
need for non-IMV, and hospitalization, which are significantly
higher in subtype C than in subtype A.
CA has been extensively used to classify individuals into groups
and also to assess phenotypes in patients with airway diseases
[27,28]. Other studies among patients with airway diseases have
shown FA is a useful technique for transforming original variables
into continuous components before including them in the CA [5].
A strong assumption of FA is that variables included in the analysis
must be continuous and normally distributed. MCA is a
multivariate technique that is similar to FA but designed for
categorical variables. There are no distributional assumptions that
limit the use of MCA. Our study includes characteristics of
ECOPD patients that were dichotomous (yes/no) or had three or
four discrete possibilities, such as arterial gas and age categories.
We used MCA for transforming the information contained in the
original categorical variables into three continuous factors, which
we interpreted as disease components. This methodology has
proven useful to eliminate superfluous variables, retain significant
Table 3. Distribution of the outcomes, clinical evolution, and need for hospitalization, by subtype.
Class
Outcome Total A B C D P*
Need for 1537 507cd 361cd 404abd 265abc ,0?001**
hospitalization (61.8) (54.3) (52.9) (71.9) (85.8)
Death 59 9cd 12d 19a 19ab ,0?001**
(2.4) (1.0) (1.8) (3.4) (6.2)
ICU Admission 36 4d 1d 11d 20abc ,0?001{
(1.5) (0.4) (0.2) (2.0) (6.5)
Need for non- 98 12d 6d 18d 62abc ,0?001`
IMV (3.9) (1.3) (0.9) (3.2) (20.1)
Other serious 547 236d 182cd 100bd 29abc ,0?0011
complications (22.0) (25.3) (26.7) (17.8) (9.4)
Total 2487 934 682 562 309
(37.6) (27.4) (22.6) (12.4)
Classes have been labeled in alphabetical order. Each cell shows the number of patients and column percentage. Abbreviations used in the text: intensive care unit
(ICU), invasive mechanical ventilation (IMV).
*Statistically significant differences between groups are shown with superscripts represented by the code of the group (A, B, C and D).
**P-value based on the chi-squared test for difference in proportions between the groups using the whole sample (n = 2487).
{P-value based on the chi-squared test for difference in proportions of ICU admission using the subsample excluding the patients who died (n= 2428).
`P-value based on the chi-squared test for difference in proportions of need for non-IMV for more than two days, using the subsample excluding the patients who had a
poorer evolution (death, ICU admission) (n= 2392).
1P-value based on the chi-squared test for difference in proportions of other serious complications using the subsample excluding the patients who had a poorer
evolution (death, ICU admission or need for non-IMV for more than two days) (n= 2294).
doi:10.1371/journal.pone.0098580.t003
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correlations between other variables, create subtypes of subjects,
and describe their typology [6,29].
Our study has several strengths. Traditional statistical methods,
such as regression models or decision trees, are designed to test the
relationship between explanatory variables and one outcome, such
as mortality [30]. We aimed to create patient typologies that were
not strictly related to a specific outcome. Subtypes were identified
based strictly on the initial evaluation of the ECOPD patients in
the EDs. This is useful because classification does not depend on a
specific outcome, but it is related to several outcomes. Statistically
significant relationships between the subtypes and several key
outcomes provided proper validation of the identified subtypes.
The use of categorical variables in the analysis could, on the
surface, be seen as a weakness of the study because it has the
potential to lose information derived from the categorization of
some continuous variables. In this case, however, dealing with
categorical variables improved the results in two ways. First, we have
previously shown that observed continuous values are often
collected as categories in clinical records [15]. Therefore, more
useful information could be extracted from the clinical record in
categorical form than in continuous form. Second, using
missingness as an additional category in the analysis allowed us
to evaluate the relationship of the missingness pattern with the rest
of the variables and outcomes. All of the five negative outcomes
were located in the negative part of the first component, showing
that they were more related to observed data than to missing data.
Moreover, more severe outcome events had a higher negative
value, indicating that the presence of missing values was less
related to severe evolution than to less severe evolution. This useful
feature of MCA allowed us to conclude that the missingness
pattern was not significantly related either to the other variables
considered in the study or to the outcomes.
In conclusion, we identified four subtypes of patients with
ECOPD attending EDs, and these were associated with different
outcomes. The classification was driven by two main components:
1) the severity of the current exacerbation plus the baseline severity
of the airway obstruction; and 2) general health status as measured
by the presence of comorbidities. This work, which extends
classification systems developed for patients with stable COPD,
could help improve our understanding of the pathophysiologic
mechanisms involved in exacerbations, establish more effective
strategies of treatment, and improve the process of care and
patient prognosis.
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